全文获取类型
收费全文 | 3907篇 |
免费 | 140篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 178篇 |
儿科学 | 80篇 |
妇产科学 | 102篇 |
基础医学 | 548篇 |
口腔科学 | 29篇 |
临床医学 | 346篇 |
内科学 | 1068篇 |
皮肤病学 | 36篇 |
神经病学 | 259篇 |
特种医学 | 132篇 |
外科学 | 441篇 |
综合类 | 31篇 |
一般理论 | 3篇 |
预防医学 | 179篇 |
眼科学 | 81篇 |
药学 | 294篇 |
中国医学 | 2篇 |
肿瘤学 | 267篇 |
出版年
2024年 | 5篇 |
2023年 | 28篇 |
2022年 | 160篇 |
2021年 | 243篇 |
2020年 | 66篇 |
2019年 | 105篇 |
2018年 | 135篇 |
2017年 | 89篇 |
2016年 | 102篇 |
2015年 | 113篇 |
2014年 | 169篇 |
2013年 | 217篇 |
2012年 | 316篇 |
2011年 | 353篇 |
2010年 | 174篇 |
2009年 | 114篇 |
2008年 | 237篇 |
2007年 | 236篇 |
2006年 | 272篇 |
2005年 | 227篇 |
2004年 | 225篇 |
2003年 | 199篇 |
2002年 | 139篇 |
2001年 | 13篇 |
2000年 | 6篇 |
1999年 | 7篇 |
1998年 | 14篇 |
1997年 | 10篇 |
1996年 | 11篇 |
1995年 | 11篇 |
1994年 | 5篇 |
1993年 | 7篇 |
1992年 | 8篇 |
1991年 | 6篇 |
1990年 | 11篇 |
1989年 | 7篇 |
1988年 | 7篇 |
1987年 | 4篇 |
1985年 | 2篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 3篇 |
1971年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有4076条查询结果,搜索用时 15 毫秒
71.
Primary coronary angioplasty with stent implantation in a patient with dextrocardia - a case report 总被引:1,自引:0,他引:1
A case of a 45-year-old male with acute myocardial infarction and dextrocardia is presented. The patient underwent successful primary coronary angioplasty with direct stenting. Difficulties in establishing diagnosis and treating patients with dextrocardia and chest pain are discussed. 相似文献
72.
Owecki M Horst-Sikorska W Kaczmarek M Słomski R Sowiński J 《Polskie Archiwum Medycyny Wewn?trznej》2003,109(2):143-148
Sulfonylureas are used in treatment of diabetes. Resistance to these derivatives is a therapeutical problem. Sulfonylureas act through sulfonylurea receptor 1 (SUR1) in the beta cell. SUR1 also enhances a physiological secretion of insulin induced by an increase of glucose concentration. It may be expected that polymorphism of SUR1 gene can lead to beta cell dysfunction and resistance to sulfonylureas. The aim of this study was to examine the frequency of polymorphism in exon 22 of SUR1 gene and its correlation with type 2 diabetes mellitus and sulfonylurea treatment failure. The group consisted of 42 patients with type 2 diabetes. The controls were 46 persons with proper glucose tolerance. Polymorphism was found in 5 patients and in 1 control person. Neither statistically significant difference of polymorphism frequency nor correlation between polymorphism and sulfonylurea failure was found due to a low number of cases. Polymorphism of exon 22 of SUR1 gene appeared more frequent in diabetic than in non-diabetic subjects but this was statistically not significant. 相似文献
73.
Chwyczko T Sterliński M Maciag A Firek B Labecka A Jankowska A Kośmicki M Kowalik I Malczewska B Szwed H 《Kardiologia polska》2008,66(4):406-12; discussion 413-4
BACKGROUND: Cardiac resynchronisation therapy (CRT) has become a valuable therapeutic tool in patients with advanced chronic heart failure (CHF). The search for optimal methods for the assessment of CRT efficacy is still underway. AIM: To evaluate the impact of implantation of CRT devices in patients with CHF on adaptation of circulatory and respiratory systems to maximal exercise assessed by cardiopulmonary exercise tests (CPX) and 6-minute walking tests (6MWT). METHODS: We investigated 27 patients (22 males, 5 females, 61.2+/-9.1 years) with a CRT device implanted due to advanced CHF, which resulted from ischaemic or dilated cardiomyopathy. All patients before implantation underwent echocardiography, CPX with expired gas analysis and 6MWT. Investigations were repeated at 3-6 months after CRT implantation. In CPX we evaluated peak oxygen uptake (peak VO2), oxygen pulse, maximal minute ventilation-carbon dioxide production (VE/VCO2 (max)), and its slope (VE/VCO2 slope) and VE/VO2 slope, VO2 in anaerobic threshold (AT), and cardiac and respiratory reserve. In 6MWT we evaluated walking distance and heart rate and blood pressure response to exercise. RESULTS: We noted statistically higher mean peak VO2 after CRT implantation in the studied group: 11.34+/-3.38 vs. 14.56+/-3.99 ml/kg/min (p<0.0001) and 1.01 +/-0.44 vs. 1.4+/-0.55 l/min (p=0.003) and higher values of expired CO2: 1.00+/-0.43 vs. 1.43+/-0.67 l/min (p=0.004). The O2 pulse rose from 9.65+/-3.39 to 13.23+/-5.43 ml/beat (p=0.015). We also observed a significant reduction of VE/VCO2 slope from 42.34+/-13.35 before CRT to 34.77+/-6.04 after CRT (p=0.0196) and a significant decrease of VE/VO2 slope from 41.32 +/-15.46 to 34.01+/-6.27 (p=0.037). VE/VCO2 (max) fell from 58.02+/-15.86 to 50.1+/-13.14 (p=0.009). Patients estimated their dyspnoea on the Borg scale at peak exercise at 4.75+/-0.75 points before CRT and at 3.67+/-1.15 points (p=0.002) after CRT. Patients could walk a longer distance during 6MWT than before CRT (367+/-154.9 vs. 231.1+/-170.3 m, p<0.001). CONCLUSIONS: Cardiac resynchronisation therapy improves exercise tolerance measured by means of CPX and 6MWT, improves respiratory system efficiency and restores its adaptive mechanisms during exercise in patients with advanced CHF. Better exercise adaptation after CRT may be objectively measured with CPX parameters, and correlates with improvement of clinical symptoms. CPX seems to be a very helpful tool in assessing the results of CRT. 相似文献
74.
Siński M Lewandowski J Abramczyk P Nowosad H Grzelak-Szafrańiska H 《Polskie Archiwum Medycyny Wewn?trznej》2005,114(2):755-760
Short acting nitrates are commonly used to prevent the anginal pain. The purpose of the study was to compare antianginal efficacy of Pentaerythritol compositum (20 mg of pentaerythritol tetranitrate and 0.5 mg of nitroglicerine) and 0,5 mg of nitroglycerine. Twenty patients aged 45-75 years with stable angina were enrolled. Antianginal effectiveness was evaluated during treadmill test. Time to ischemic pain and/or electrocardiographic parameters of ischemia were measured. It was found that Pentaerythritol compositum was superior to nitroglycerine in preventing angina with the difference disappearing 60 minutes after drug administration. Both drugs were well tolerated. Achieved results show that Pentaerythritol compositum can be effective as antianginal drug in patients with stable angina. 相似文献
75.
Mularek-Kubzdela T Grajek S Olasińska A Seniuk W Grygier M Trojnarska O Lesiak M Cieśliński A 《International journal of cardiology》2008,127(3):433-435
Patients with exercise angina >2 months (n:13) showed significantly lower SigmaST elevation during 120 s balloon coronary occlusion than those with =<2 months (n:7), or those with angina at rest <=2 days (n:8) but similar to patients with angina at rest >2 days (n:7). These results underscore the importance of the kind and duration of angina in limiting the extent of ischemia during coronary occlusion. 相似文献
76.
Aortic intramural haematoma (AIH) is a variation of aortic dissection where blood collects within the aortic media without the presence of an intimal flap. The natural history of the disease has not yet been definitely established. Two cases of AIH type A are presented--an 81-year-old hypertensive male, and a 60-year-old male, both admitted to the hospital with sudden-onset severe chest pain. In both cases AIH type A was confirmed using computed tomography. One patient underwent successful conservative treatment, whereas another one had urgent surgery. 相似文献
77.
Pytkowski M Jankowska A Kraska A Sterliński M Kowalik I Krzyzanowski W Szwed H 《Polskie Archiwum Medycyny Wewn?trznej》2004,111(6):703-707
Aim of this prospective study was to assess quality of life (QoL), left ventricular (LV) function and exercise performance in two groups of patients (pts) with atrial fibrillation (Af) treated with: radiofrequency catheter ablation (RFA) and antiarrhythmic drugs (AA). Between 1996 and 2000 - 74 patients, 28 women, with drug refractory Af were enrolled by clinical indications for two modes of therapy: RFA and AA. RFA group consisted of 38 pts, 63.7 +/- 11.5 years old: 28 pts with RF AV Node ablation and pacemaker implantation (PI) and 10 pts with AV Node modification or right atrial isthmus RF ablation due to Af conversion to atrial flutter (Aflu) during medical therapy. AA group consisted of 36 pts, aged 59.7 +/- 13.8 years. Patients from RFA group suffered significantly more serious diseases than pts from AA group. No significant (sign.) differences between two groups were found in age, gender, arrhythmia history and number of AA taken. Pts were analyzed before entry, after 3 and 12 months of follow-up (3 mo. FU, 12 mo. FU) with following indices: LV function (Echo: EF & FS), exercise performance (treadmill test), QoL questionnaires, number of hospital admissions connected to arrhythmia or procedures (RFA & PI), number of AA drugs taken in RFA group. RFA group: Two deaths occurred due to end stage respiratory insufficiency (COPD), one pt required reposition of pacemaker lead. AA group: 3 pts required RFA due to uncontrolled Af/Aflu (AV Node ablation with PI - 1 pt, right atrial isthmus ablation - 2 pts). Analysis of two patients groups: LV function: Sign. improvement (EF & FS) in both groups in 12 mo. FU; Exercise performance: no sign. changes in 3 and 12 mo. FU. QoL: Arrhythmia scale: 3 mo. FU sign. reduction in both groups; 12 mo. FU reduction in RFA group only; Anxiety scale: 3 and 12 mo. FU sign. reduction of anxiety level in RFA group; Exercise and activity scales: 3 and 12 mo. FU sign. improvement in RFA group. During 3 and 12 mo. FU sign. less pts from RFA group required hospital admission versus pts from AA group. Sign. reduction in AA was noted in RFA group. Patients with symptomatic Af treated with RFA benefit from this kind of therapy more than patients treated with AA. Quality of life improvement visible in short term observation in patients from RFA group is still present after one year observation. Improvement in LV function is observed after one year in both groups of pts with Af. 相似文献
78.
Dragana Nikolic Manfredi Rizzo Dimitri P Mikhailidis Norman C Wong Maciej Banach 《Expert opinion on investigational drugs》2015,24(10):1389-1398
Introduction: RVX-208 is a first-in-class, orally active, novel small molecule in development by Resverlogix Corporation (Calgary, AB, Canada). It acts through an epigenetic mechanism by inhibiting the bromodomain and extraterminal (BET) family of proteins, increasing apolipoprotein A-I (apoA-I) and targeting high-density lipoprotein (HDL) metabolism, including generating of nascent HDL and increased larger HDL particles, resulting in the stimulation of reverse cholesterol transport. RVX-208 also has a beneficial effect on inflammatory factors known to be involved in atherosclerosis and plaque stability. New therapeutic strategies are needed for patients with atherosclerosis.Areas covered: In this review, the authors evaluate the use of RVX-208 as an agent for the treatment of atherosclerosis. The article is based on a literature search considering both animal and human studies available on PubMed as well as Media Releases from the Resverlogix Corporation.Expert opinion: The current evidence suggests promising beneficial effects of this novel drug in the prevention and treatment of atherosclerosis and other metabolic disorders. Its unique mechanism of action is encouraging; it affects several pathways and has a modest effect on HDL levels. There is also a shift in particle size to larger HDL particles, which may have potent atheroprotective effects. Future clinical development is needed, including safety assessment. 相似文献
79.
80.
Maciej Cabanski Brett Fields Stephanie Boue Natalia Boukharov Hector DeLeon Natalie Dror Marcel Geertz Emmanuel Guedj Anita Iskandar Ulrike Kogel Celine Merg Michael J. Peck Carine Poussin Walter K. Schlage Marja Talikka Nikolai V. Ivanov Julia Hoeng Manuel C. Peitsch 《Inflammation research》2015,64(7):471-486